[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Sarini J, Bocciolini C, Fournier C, Penel N, Kara A, Van JT, Lefebvre JL: [Induction chemotherapy and larynx preservation: is such practice useful?]. Bull Cancer; 2002 Apr;89(4):411-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Induction chemotherapy and larynx preservation: is such practice useful?].
  • BACKGROUND: Surgery followed by irradiation is considered to be the standard treatment but require frequently a total laryngectomy.
  • Chemotherapy followed by irradiation is available in larynx and hypopharynx squamous cell carcinoma (SCC) treatment.
  • Are results obtained in daily induction chemotherapy usefulness identical to results obtained in larynx preservation studies?
  • PATIENTS AND METHOD: We conducted a retrospective study on patients treated at centre Oscar-Lambret, Lille, from 1986 to 1995, by chemotherapy followed by definitive radiotherapy or by surgery and radiotherapy for laryngeal or hypopharyngeal cancer treatment.
  • All patients were naive of previous head and neck SCC and a surgical treatment, requiring total laryngectomy, should be proposed with curative intent.
  • Induction chemotherapy associated cisplatin (100 mg/m2) on day 1 and 5-fluorouracil (5FU)(1,000 mg/m2) on days 1-4 or 1-5.
  • If case of non-responder, patients underwent surgical treatment followed by irradiation.
  • For chemotherapy-related toxic reactions, the exclusive statistical difference observed was haematological toxicity grade III and IV after the second cycle (0 pt in group 1 vs 8 pts in group 2; p =.02).
  • After initial treatment, complete response was achieved without statistical difference between the groups (88.2% vs 78%; p =.27).
  • A surgical procedure was performed in 46 cases without difference according to the reference group and functional larynx preservation was 55.8% (29/52) in group 1 and 53.6% (30/56) in group 2.
  • Cancer was the first cause of death in both groups.
  • The overall survival of the population (108 patients) was 81.5% at one year, 49.6% at 3 years and 35.3% at 5 years with a median survival of 3 years.
  • Some parameters influenced the overall survival like T (p =.04), response to chemotherapy (p=.006), extra capsular spread (p = 0.03) and response after completion treatment.
  • CONCLUSION: Induction chemotherapy is available for larynx preservation but cannot be considered as a standard treatment.
  • Recent publication, on increase postoperative infection after chemotherapy, should be evaluated in clinical trial.
  • Larynx preservation remains an interesting point of view for patients but stay an optional procedure and not a reference.
  • [MeSH-major] Carcinoma, Squamous Cell. Hypopharyngeal Neoplasms. Laryngeal Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Laryngectomy / methods. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12016041.001).
  • [ISSN] 0007-4551
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


2. Chesnay E, Babin E, Constans JM, Agostini D, Bequignon A, Regeasse A, Sobrio F, Moreau S: Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome. J Nucl Med; 2003 Apr;44(4):526-32
Hazardous Substances Data Bank. (L)-Methionine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early response to chemotherapy in hypopharyngeal cancer: assessment with (11)C-methionine PET, correlation with morphologic response, and clinical outcome.
  • Neoadjuvant chemotherapy in hypopharyngeal cancer globally improves survival, but some patients do not respond to chemotherapy and adjuvant therapy is delayed.
  • Prediction of response to chemotherapy may allow physicians to optimize planned treatment.
  • The aim of this study was to compare treatment response assessed early with (11)C-methionine PET and morphologic response assessed after treatment completion with MRI.
  • METHODS: Thirteen patients with previously untreated squamous cell carcinoma of the hypopharynx, T3 or T4, were included.
  • All patients received 3 courses of chemotherapy comprising cisplatin and 5-fluorouracil. (11)C-Methionine PET was performed before and after the first course of chemotherapy.
  • Posttreatment response was assessed with MRI, which was performed before the first course and after treatment completion, and expressed in relative variation of tumor volume.
  • CONCLUSION: (11)C-Methionine PET provides early useful information about changes in tumor metabolism induced by chemotherapy in hypopharynx cancer. (11)C-Methionine PET measurements correlate with end-of-treatment response evaluated with MRI and may thus be helpful to physicians in treatment planning by avoiding unnecessary chemotherapy courses for nonresponding patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radionuclide imaging. Methionine. Tomography, Emission-Computed / methods
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Statistics as Topic. Treatment Outcome

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12679395.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 58576-49-1 / carbon-11 methionine; AE28F7PNPL / Methionine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


3. Quer M, León X: [Organ preservation in laryngeal and hypopharyngeal cancer]. Acta Otorrinolaringol Esp; 2007 Dec;58(10):476-82
Genetic Alliance. consumer health - Laryngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Organ preservation in laryngeal and hypopharyngeal cancer].
  • [Transliterated title] Modalidades de preservación de órgano en carcinomas de laringe e hipofaringe.
  • Organ preservation in advanced laryngeal and hypopharyngeal squamous cell carcinoma has been a major target for clinical research in the last years.
  • For a long time, partial surgery and radiotherapy were the only options that could preserve the larynx.
  • Partial surgery has developed new open techniques and, with the introduction of laser it continues to have a clear role in organ preservation.
  • But, the real revolution began after 1980 with the introduction of chemotherapy that increased the options.
  • Induction chemotherapy followed by radiotherapy where response is good has allowed the larynx to be preserved in about half of the cases, without jeopardizing survival.
  • Concomitant chemoradiotherapy gives better results in preservation, and induction chemotherapy followed by concomitant chemoradiotherapy is under clinical research.
  • Finally, new targeted treatments open up new fields in clinical research.
  • With so many options and in view of the lack of a global agreement, more multidisciplinary clinical research is still needed in order to define the best strategy for each patient.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / surgery. Hypopharyngeal Neoplasms / epidemiology. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / epidemiology. Laryngeal Neoplasms / surgery. Salvage Therapy / statistics & numerical data
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Postoperative Period

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18082078.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 61
  •  go-up   go-down


Advertisement
4. Ishiguro R, Fujii M, Yamashita T, Tashiro M, Tomita T, Ogawa K, Kameyama K: CCND1 amplification predicts sensitivity to chemotherapy and chemoradiotherapy in head and neck squamous cell carcinoma. Anticancer Res; 2003 Nov-Dec;23(6D):5213-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCND1 amplification predicts sensitivity to chemotherapy and chemoradiotherapy in head and neck squamous cell carcinoma.
  • BACKGROUND: Cyclin D1 has been reported to be associated with poor prognosis in head and neck squamous cell carcinoma (HNSCC).
  • Thirty-two received neoadjuvant chemotherapy (NAC) as primary treatment and 21 with hypopharyngeal squamous cell carcinoma (HPC) received chemoradiotherapy.
  • CCND1 amplification with a homogeneously staining region (HSR) was accompanied by cyclin D1 protein overexpression (p < 0.0001).
  • CONCLUSION: Detection of CCND1 amplification using FISH may be a useful marker of sensitivity to NAC and chemoradiotherapy for HNSCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / therapy. Cyclin D1 / genetics. Head and Neck Neoplasms / genetics. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Gene Amplification. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / genetics. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / therapy. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoadjuvant Therapy. Prognosis


5. Koybasi S, Senkal CE, Sundararaj K, Spassieva S, Bielawski J, Osta W, Day TA, Jiang JC, Jazwinski SM, Hannun YA, Obeid LM, Ogretmen B: Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J Biol Chem; 2004 Oct 22;279(43):44311-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas.
  • In this study, endogenous long chain ceramides were measured in 32 human head and neck squamous cell carcinoma (HNSCC) and 10 nonsquamous head and neck carcinoma tumor tissues, as compared with adjacent noncancerous tissues, by liquid chromatography/mass spectroscopy.
  • Interestingly, only one specific ceramide, C(18:0)-ceramide, was selectively down-regulated in the majority of HNSCC tumor tissues.
  • On the other hand, in nonsquamous tumor tissues, this selectivity for C18-ceramide was not detected.
  • These roles were examined by reconstitution of C18-ceramide at physiologically relevant concentrations in UM-SCC-22A cells (squamous cell carcinoma of hypopharynx) via overexpression of mammalian upstream regulator of growth and differentiation factor 1 (mUOG1), a mouse homologue of longevity assurance gene 1 (mLAG1), which has been shown to specifically induce the generation of C18-ceramide.
  • Liquid chromatography/mass spectroscopy analysis showed that overexpression of the mLAG1/mUOG1 resulted in increased levels of only C(18:0)-ceramide by approximately 2-fold, i.e. concentrations similar to those of normal head and neck tissues.
  • Importantly, increased generation of C18-ceramide by mLAG1/mUOG1 inhibited cell growth (approximately 70-80%), which mechanistically involved the modulation of telomerase activity and induction of apoptotic cell death by mitochondrial dysfunction.
  • In conclusion, this study demonstrates, for the first time, a biological role for LAG1 and C18-ceramide in the regulation of growth of HNSCC.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Ceramides / chemistry. Head and Neck Neoplasms / drug therapy. Membrane Proteins / biosynthesis. Proteins / physiology. Saccharomyces cerevisiae Proteins / biosynthesis
  • [MeSH-minor] Animals. Apoptosis. Cell Division. Cell Line, Tumor. Chromatography, Liquid. Coloring Agents / pharmacology. DNA, Complementary / metabolism. Humans. Mass Spectrometry. Membrane Potentials. Mice. Mitochondria / metabolism. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sphingosine N-Acyltransferase. Telomerase / metabolism. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Trypan Blue / pharmacology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. Trypan blue .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15317812.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG-16583; United States / NIA NIH HHS / AG / AG06168; United States / NCI NIH HHS / CA / CA-097132; United States / NCI NIH HHS / CA / CA-88932
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ceramides; 0 / Coloring Agents; 0 / DNA, Complementary; 0 / LAG1 protein, S cerevisiae; 0 / Membrane Proteins; 0 / N-stearoylsphinganine; 0 / Proteins; 0 / RNA, Messenger; 0 / Saccharomyces cerevisiae Proteins; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; EC 2.3.1.24 / CERS1 protein, human; EC 2.3.1.24 / Sphingosine N-Acyltransferase; EC 2.7.7.49 / Telomerase; I2ZWO3LS3M / Trypan Blue
  •  go-up   go-down


6. Suzuki M, Terada A, Ogawa T, Suzuki H, Hasegawa Y: [Salvage surgery for radiation failure in oral, oropharyngeal, and hypopharyngeal squamous cell carcinoma]. Nihon Jibiinkoka Gakkai Kaiho; 2007 Jun;110(6):461-5
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Salvage surgery for radiation failure in oral, oropharyngeal, and hypopharyngeal squamous cell carcinoma].
  • Few reports have covered salvage surgery after radiotherapy, especially with chemotherapy for oral, oropharyngeal, and hypopharyngeal squamous cell carcinoma.
  • We analyzed postoperative complications and prognosis after salvage surgery for local recurrence after definitive radiotherapy.
  • Subjects were 37 patients with oral, oropharyngeal, and hypopharyngeal squamous cell carcinoma treated from 1994 to 2003.
  • The complication rate was significantly high in the reconstructive operation group (p = 0.031) and the chemotherapy group (p = 0.049).
  • We found that salvage surgery after definitive radiotherapy was effective for recurrent oral, oropharyngeal, and hypopharyngeal squamous cell carcinoma.
  • We stress the need to pay attention to postoperative complications in reconstructive operation and chemotherapy groups.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Hypopharyngeal Neoplasms / surgery. Mouth Neoplasms / surgery. Oropharyngeal Neoplasms / surgery. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Survival Rate. Treatment Failure

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633115.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Tian WD, Zeng ZY, Yu WB, Li XP: [Application of SELDI-TOF-MS in establishing a model for predicting radiotherapy response of hypopharyngeal cancers]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun;30(6):1282-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of SELDI-TOF-MS in establishing a model for predicting radiotherapy response of hypopharyngeal cancers].
  • OBJECTIVE: To detect the serum proteomic fingerprints in patients with hypopharyngeal squamous cell carcinoma (HPSCC) by surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) protein chip array technique.
  • RESULTS: The protein profiles of HPSCC serum were analyzed according to the clinical and pathological features of the patients and their treatment response.
  • No significant difference was found in the serum proteins between chemotherapy-sensitive patients and the insensitive patients (P>0.05), but 5 proteins were identified to be overexpressed in the sensitive patients (P < / = 0.05).
  • Radiotherapy-sensitive HPSCC patients were segregated from the insensitive group with a sensitivity of 86.67% and specificity of 100%.
  • CONCLUSION: The serum protein at the m/z value of 6115.74 is overexpressed in radiotherapy-sensitive HPSCC patients.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / radiotherapy. Proteome / analysis. Radiation Tolerance. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20584658.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome
  •  go-up   go-down


8. Oueslati Z, Zeglaoui I, Touati S, Gritli S, Nasr C, Benna F, Boussen H, Mokni N, Gamoudi A, El-May A, Ladgham A: [Hypopharyngeal squamous cell carcinoma: retrospective study of 149 patients]. Cancer Radiother; 2004 Dec;8(6):358-63
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hypopharyngeal squamous cell carcinoma: retrospective study of 149 patients].
  • [Transliterated title] Carcinome épidermoïde de l'hypopharynx: étude rétrospective de 149 traitements à visée curative.
  • PURPOSE: Hypopharyngeal squamous cell carcinoma is associated to one of the most unfavorable prognosis among the cancers of the head and neck.
  • The purpose of this study is to analyze its therapeutic modalities in the Salah-Azaïz Institute (Tunis) and to compare their results.
  • PATIENTS AND METHOD: This retrospective study concerns 271 hypopharyngeal squamous cell carcinomas, compiled in the Carcinologic Surgery Department of Head and Neck of the Salah-Azaïz Institute over a period of 25 years (from 1977 to 2002).
  • The indication of a curative treatment was initially retained for 149 (55%) patients, who were the only ones retained for the analysis of results.
  • RESULTS: We retained the indication of a protocol including surgery and postoperating radiotherapy for 26.2% of the patients.
  • For 13.5% of the patients, postoperating radiotherapy was permanently interrupted because of a gradual deterioration of the patients' health in the course of treatment.
  • We indicated a protocol of conservation of organ with induction chemotherapy for 21 patients (14.1%).
  • All the patients selected for chemotherapy died in the course of treatment.
  • CONCLUSION: Although the induction chemotherapy entails a particularly high death rate in our series, the association surgery-radiotherapy and the exclusive radiotherapy seem to be similarly efficient for the treatment of the hypopharyngeal carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Hypopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Esophagectomy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoadjuvant Therapy. Pharyngectomy. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15619380.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Erdağ TK, Karas C, Ikiz AO, Güneri EA, Ceryan K, Sarioğlu S: [The incidence of level I metastasis in laryngopharyngeal squamous cell carcinoma]. Kulak Burun Bogaz Ihtis Derg; 2003 Dec;11(6):166-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The incidence of level I metastasis in laryngopharyngeal squamous cell carcinoma].
  • OBJECTIVES: We investigated the incidence of level I metastasis in patients with laryngeal and hypopharyngeal squamous cell carcinoma (SCC).
  • PATIENTS AND METHODS: The records of 126 patients who underwent primary tumor excision with radical neck dissection (RND) or its modifications for laryngeal or hypopharyngeal SCC were retrospectively reviewed.
  • Patients treated with selective neck dissection (SND) or preoperative chemotherapy and/or radiation therapy were excluded.
  • RESULTS: Of 155 RND or modified RND performed for 113 laryngeal and 13 hypopharyngeal SCC, lymph node metastases were detected in 51 specimens, all of which spared level I.
  • CONCLUSION: Selective neck dissection sparing level I may be appropriate for clinically and radiologically N0 patients with laryngopharyngeal carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Hypopharyngeal Neoplasms / epidemiology. Laryngeal Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15567930.001).
  • [ISSN] 1300-7475
  • [Journal-full-title] Kulak burun boğaz ihtisas dergisi : KBB = Journal of ear, nose, and throat
  • [ISO-abbreviation] Kulak Burun Bogaz Ihtis Derg
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


10. Kuropkat C, Rudolph P, Parwaresch R, Werner JA: Ki-S1--a prognostic marker for hypopharyngeal carcinoma with potential predictive value for response to chemotherapy. Anticancer Res; 2003 Sep-Oct;23(5A):3965-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-S1--a prognostic marker for hypopharyngeal carcinoma with potential predictive value for response to chemotherapy.
  • BACKGROUND: It has previously been shown that the proliferative activity, determined by means of the monoclonal antibody Ki-S11 against the Ki-67 protein, is a significant prognostic factor for squamous cell carcinoma of the hypopharynx (SCCH).
  • Survival probabilities over an observation time of 72 months were calculated by Kaplan-Meier analysis.
  • CONCLUSION: Topoisomerase II alpha is also the target of many antineoplastic drugs and it has been proposed that its expression in tumor cells correlates with chemosensitivity.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / enzymology. DNA Topoisomerases, Type II / metabolism. Hypopharyngeal Neoplasms / enzymology. Nuclear Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / metabolism. Cell Division / physiology. DNA-Binding Proteins. Epitopes / analysis. Epitopes / immunology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Predictive Value of Tests

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14666704.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Epitopes; 0 / Nuclear Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


11. Correia O, Ribas F, Azevedo R, Rodrigues H, Delgado L: Gangrene of the fingertips after bleomycin and methotrexate. Cutis; 2000 Oct;66(4):271-2, 274
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The increased use of cytostatic drugs, which are sometimes used in combination chemotherapy, may result in new and unusual cutaneous side effects.
  • We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fingers / pathology. Gangrene / chemically induced
  • [MeSH-minor] Bleomycin / adverse effects. Carcinoma, Squamous Cell / drug therapy. Cyanosis / chemically induced. Humans. Ischemia / chemically induced. Male. Methotrexate / adverse effects. Middle Aged. Pharyngeal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Gangrene.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11109149.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


12. Nakamura K, Shioyama Y, Sasaki T, Ohga S, Saku M, Urashima Y, Yoshitake T, Nakashima T, Kuratomi Y, Komune S, Terashima H, Honda H: Chemoradiation therapy with or without salvage surgery for early squamous cell carcinoma of the hypopharynx. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):680-3
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation therapy with or without salvage surgery for early squamous cell carcinoma of the hypopharynx.
  • PURPOSE: Early squamous cell carcinoma of the hypopharynx is a rare clinical entity.
  • Our objective was to analyze the outcome of patients with early hypopharyngeal cancer treated with curative radiotherapy or the combination of preoperative radiotherapy with surgery.
  • METHODS AND MATERIALS: Forty-three patients with Stage I-II hypopharyngeal cancer were initially treated with 30-40 Gy of irradiation with or without chemotherapy.
  • Thirty-two patients (74.4%) who demonstrated a complete response continued to receive further radiotherapy, with a median total dose of 61.2 Gy.
  • The disease-specific survival rates according to the T-category were 100% for patients with T1 disease and 87.2% for patients with T2 disease (p = 0.32).
  • Four patients died of hypopharyngeal cancer, and 5 died of second-primary esophageal cancer.
  • CONCLUSIONS: A majority of patients with early hypopharyngeal cancer was curable.
  • However, second malignancies influenced the overall outcome of patients with early hypopharyngeal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Hypopharyngeal Neoplasms / radiotherapy. Hypopharyngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary. Pharyngectomy. Radiotherapy Dosage. Salvage Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936545.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Specenier PM, Lalami Y, Vermorken J, Lacombe D, El-Hariry I, Bogaerts J, Awada A: EORTC 24051: Unexpected side effects of a phase I study of TPF induction chemotherapy (IC) followed by chemoradiation (CRT) with lapatinib (LAP), a dual EGFR/ErbB2 inhibitor, in patients with locally advanced larynx and hypopharynx squamous cell carcinoma (LA-LxHxSCC). J Clin Oncol; 2009 May 20;27(15_suppl):6017

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EORTC 24051: Unexpected side effects of a phase I study of TPF induction chemotherapy (IC) followed by chemoradiation (CRT) with lapatinib (LAP), a dual EGFR/ErbB2 inhibitor, in patients with locally advanced larynx and hypopharynx squamous cell carcinoma (LA-LxHxSCC).
  • : 6017 Background: CRT is considered a standard approach for LA-LxHxSCC.
  • The addition of LAP was investigated in combination with a sequential therapeutic approach (IC→ CRT).
  • METHODS: Eligible tumors were SCCHN: T3-T4 larynx (Lx), T2-T4 hypopharynx (Hx) N0-3 M0.
  • Renal toxicity was observed among these 3 pts (grade 4 [n = 1], grade 2 [n=1] and grade 1 [n=1]), with 1 DLT, leading to treatment interruption in this group.
  • As LAP plus cisplatinum plus RT was feasible in another study, a second cohort was conducted in 4 pts, receiving LAP at the same dosage, and docetaxel (T) was only introduced from cycle 2 of IC to see what is the role of T in the observed side effect.
  • CONCLUSIONS: These data suggest that LAP should not be combined with TPF IC regimen for LA-LxHxSCC due to prohibited toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962424.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Lefebvre J, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Bardet E, Tuchais C, Calais G, Groupe Oncologie Radiotherapie Tete Et Cou (GORTEC): Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study. J Clin Oncol; 2009 May 20;27(15_suppl):6010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6010 Background: Induction chemotherapy (ICT) followed by irradiation (RT) and concurrent chemoradiotherapy (CRT) are validated options for LP.
  • METHODS: Previously untreated patients (pts) with larynx or hypopharynx squamous cell carcinoma and candidates for a total laryngectomy were eligible for this randomized phase II study.
  • In case of response ≥ 50 % pts were randomized to receive either in arm A: RT (70 Gy) with cisplatin (100 mg/m<sup>2</sup> on days 1, 22 and 43 of RT) or in arm B: Cetuximab (400 mg/m<sup>2</sup> loading dose before RT and 250 mg/m<sup>2</sup> on the first day of the 7 weeks of RT.
  • Primary endpoint was LP 3 months after treatment, secondary endpoints were larynx function preservation at 18 months, quality of function and tolerance to treatment.
  • RESULTS: From March 2006 to April 2008 (end of accrual), 153 pts with stage III-IV larynx/hypopharynx cancer were enrolled in the study and could start ICT.
  • 3 months after treatment there was no significant difference in LP (93% in arm A and 96% in arm B).
  • In arm A 50% of pts had cisplatin-related toxicity (definitive in 52% the cases) while in arm B 26 % of patients had cetuximab-related toxicity (definitive in only 1 case).
  • There was no CRT treatment-related death.
  • ICT followed by RT with concurrent cetuximab appeared better tolerated than with concurrent cisplatin with the same LP rate 3 months after treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962406.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Bastit L, Blot E, Debourdeau P, Menard J, Bastit P, Le Fur R: Influence of the delay of adjuvant postoperative radiation therapy on relapse and survival in oropharyngeal and hypopharyngeal cancers. Int J Radiat Oncol Biol Phys; 2001 Jan 1;49(1):139-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of the delay of adjuvant postoperative radiation therapy on relapse and survival in oropharyngeal and hypopharyngeal cancers.
  • PURPOSE: To determine whether the delay between surgery and the beginning of radiation therapy influences survival or the risk of local-regional relapse in oropharyngeal or hypopharyngeal squamous cell carcinomas.
  • METHODS AND MATERIALS: From 2052 patients referred to the Henri Becquerel Center for the radiation therapy of an oropharyngeal or hypopharyngeal cancer between January 1, 1981 and December 31, 1992, 420 were included in a retrospective study.
  • Exclusion criteria were another cancer, metastasis, incomplete resection, lack of homolateral lymph node resection, or previous chemotherapy.
  • Radiation therapy delivered 45 to 75 Gy on initial location and lymph node.
  • RESULTS: The delay between surgery and radiation therapy was not found to be a significant prognostic factor for survival or risk of local-regional relapse.
  • CONCLUSION: In patients with oropharyngeal or hypopharyngeal squamous cell carcinoma, the delay between surgical procedure and radiation therapy does not influence survival or risk of local-regional relapse.
  • Radiation therapy might be subjected to complete healing in these patients.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11163507.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Saussez S, Cucu DR, Decaestecker C, Chevalier D, Kaltner H, André S, Wacreniez A, Toubeau G, Camby I, Gabius HJ, Kiss R: Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol; 2006 Jul;13(7):999-1009
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer.
  • BACKGROUND: Eighty percent of hypopharyngeal squamous cell carcinoma patients have advanced stages (III and IV) of the disease, and biological markers are required to predict high-risk head and neck squamous cell carcinoma patients in need of highly aggressive treatments after surgery to improve the survival rate.
  • We analyzed the potential prognostic value of galectin 7 in a series of 81 stage IV hypopharyngeal SCCs because galectin 7 is an emerging marker involved in the epidermal development of pluristratified epithelia and in epidermal cell migration.
  • METHODS: The immunohistochemical expression of galectin 7 was determined on a series of 81 stage IV hypopharyngeal SCCs and was compared with that of galectins 1 and 3.
  • RESULTS: High levels of galectin 7 expression were associated with rapid recurrence rates and dismal prognoses in these 81 stage IV hypopharyngeal SCCs, a feature not observed with galectin 3 and one observed weakly, if at all, with galectin 1.
  • CONCLUSIONS: These data suggest that the immunohistochemical determination of galectin 7 expression in the case of high-risk hypopharyngeal cancers is a meaningful tool to identify patients who should benefit from aggressive postsurgical adjuvant therapy after surgery, including not only radiotherapy, but also chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Galectins / metabolism. Hypopharyngeal Neoplasms / metabolism. Hypopharyngeal Neoplasms / mortality. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Female. Galectin 3 / metabolism. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16788763.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / Galectins; 0 / LGALS7 protein, human
  •  go-up   go-down


17. Chung PS, Kim HG, Rhee CK, Saxton RE: Anticancer effect of combined intratumor cisplatin injection and interstitial KTP laser therapy on xenografted squamous cell carcinoma. J Clin Laser Med Surg; 2003 Feb;21(1):23-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticancer effect of combined intratumor cisplatin injection and interstitial KTP laser therapy on xenografted squamous cell carcinoma.
  • OBJECTIVE: This study was conducted to evaluate the synergistic effect of cisplatin and interstitial KTP laser therapy induced hyperthermia in vitro and in vivo (interstitial laser chemotherapy, ILCT).
  • METHODS: In vitro study: human hypopharyngeal squamous carcinoma cell line (SNU-1041) was incubated in 1 mL of media containing various concentrations (0, 1, 2, 5, 10, 20, 50, 100 ng/mL) of cisplatin in 37 degrees and 43 degrees C for 2 hours.
  • The viability of the cell was evaluated by MTT assay.
  • In vivo study: human squamous cell carcinoma tumors were grown as subcutaneous transplants in nude mice and injected into tumor with cisplatin-epigel 100 microg, followed by interstitial laser therapy (ILT) via 0.6-mm diffuser fiber tips (532 nm, 1.0J/mm(3)).
  • In vivo study: the tumor volume in 4 weeks after treatment was 179 mm(3) in ILT group and 27 mm(3) in ILCT group.
  • CONCLUSION: These results suggest ILCT may become an effective treatment for head and neck carcinoma with minimal functional deficit.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / administration & dosage. Low-Level Light Therapy / methods
  • [MeSH-minor] Animals. Brachytherapy. Combined Modality Therapy. Humans. Hyperthermia, Induced. Hypopharyngeal Neoplasms. Injections, Intralesional. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / radiation effects

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12614556.001).
  • [ISSN] 1044-5471
  • [Journal-full-title] Journal of clinical laser medicine & surgery
  • [ISO-abbreviation] J Clin Laser Med Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


18. Sarini J, Fournier C, Lefebvre JL, Bonafos G, Van JT, Coche-Dequéant B: Head and neck squamous cell carcinoma in elderly patients: a long-term retrospective review of 273 cases. Arch Otolaryngol Head Neck Surg; 2001 Sep;127(9):1089-92
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck squamous cell carcinoma in elderly patients: a long-term retrospective review of 273 cases.
  • For a long time these patients were not considered good candidates to receive aggressive therapy and probably were inadequately treated in many instances.
  • OBJECTIVE: To assess the outcome of patients older than 74 years who had had head and neck squamous cell carcinoma.
  • MATERIALS AND METHODS: In our database of 4610 consecutive patients with head and neck squamous cell carcinomas who were evaluated and treated at the Centre Oscar Lambret, Northern France Comprehensive Cancer Center, Lille, over a 10-year period (1974-1983), we identified 273 patients who were 75 years or older.
  • There were no differences for primary site except for hypopharyngeal squamous cell carcinoma that occurred less frequently in the elderly patients (8.8% vs 14.5%, borderline significance P =.02).
  • There were no differences for TNM stage grouping, histological classification, incidences of previous cancer, and comorbidities.
  • Surgery was performed in a smaller proportion of older patients (13.9% vs 27.4%, P<.001, for the primary site and 15.4% vs 35.6%, P<.001, for those occurring in the neck) as well as chemotherapy that was delivered in 5.5% vs 17.7% (P<.001).
  • On the contrary, there was no difference in radiotherapeutic treatments.
  • Tolerance to treatment was similar and there was the same proportion of persistent diseases 2 months after completion of the overall treatment (27.8% vs 25.4%, P =.94).
  • There was no difference in treatment-related deaths (11.1% vs 9.3%).
  • CONCLUSIONS: Head and neck squamous cell carcinoma in elderly patients did not seem to have a significantly different outcome when compared with head and neck squamous cell carcinoma occurring in younger patients.
  • When properly monitored, conventional therapies seem feasible in older patients.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11556858.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Tamura K, Yoshinaga T, Tanino M, Kimura T, Yamada N, Nishimura M, Fukuda S, Nishihara H, Shindoh M, Tanaka S: Hypopharyngeal squamous cell carcinoma producing both granulocyte colony-stimulating factor and parathyroid hormone-related protein. Pathol Int; 2008 Oct;58(10):652-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypopharyngeal squamous cell carcinoma producing both granulocyte colony-stimulating factor and parathyroid hormone-related protein.
  • Laryngoscopy indicated hypopharyngeal tumor histologically diagnosed as squamous cell carcinoma (SCC).
  • A combination of radiotherapy and chemotherapy was performed for 2 months, and the hypopharyngeal lesion completely regressed.
  • Subsequently, positron emission tomography (PET) showed multiple metastases to several organs including the liver, spine, skull, and thigh.
  • Two months after readmission, the patient died with no success of chemotherapy.
  • Thus, a certain population of hypopharyngeal cancer producing G-CSF and PTHrP, spread to various organs and contributed to the rapid progression and poor prognosis.
  • This case is presented with a discussion of several other cases in the literature.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Granulocyte Colony-Stimulating Factor / blood. Hypopharyngeal Neoplasms / metabolism. Parathyroid Hormone-Related Protein / blood
  • [MeSH-minor] Combined Modality Therapy. Deglutition Disorders / pathology. Fatal Outcome. Female. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Parathyroid carcinoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801086.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


20. Gupta T, Chopra S, Agarwal JP, Laskar SG, D'cruz AK, Shrivastava SK, Dinshaw KA: Squamous cell carcinoma of the hypopharynx: single-institution outcome analysis of a large cohort of patients treated with primary non-surgical approaches. Acta Oncol; 2009;48(4):541-48
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the hypopharynx: single-institution outcome analysis of a large cohort of patients treated with primary non-surgical approaches.
  • INTRODUCTION: Hypopharyngeal cancers have extensive submucosal spread, high risk of nodal involvement and relatively high propensity of distant metastases.
  • Contemporary paradigms for hypopharyngeal cancers aim to maximize loco-regional control while attempting to preserve laryngo-pharyngeal form and function.
  • AIMS: To retrospectively review outcome of large cohort of patients with hypopharyngeal cancers treated with curative intent radiotherapy with or without systemic chemotherapy in an academic tertiary referral centre.
  • MATERIAL AND METHODS: Medical records of patients with hypopharyngeal cancers treated with primary non-surgical approaches over a 15-year period were reviewed retrospectively.
  • RESULTS: Electronic search of database identified 501 patients with hypopharyngeal cancers treated with definitive radiotherapy.
  • The median age was 55 years (range 20-87 years) and median radiotherapy dose 70 Gy (range 5.4-72 Gy).
  • With a mean follow-up period of 22 months (median 12 months), the 3-year LRC and DFS was 47.1% and 40.9% respectively.
  • CONCLUSION: This is an outcome analysis of the largest cohort of patients with hypopharyngeal cancers managed with primary non-surgical approaches.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Analysis of Variance. Chemotherapy, Adjuvant / adverse effects. Cohort Studies. Disease-Free Survival. Female. Humans. Male. Medical Records. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Retrospective Studies. Risk Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18979267.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


21. Nakamura K, Shioyama Y, Kawashima M, Saito Y, Nakamura N, Nakata K, Hareyama M, Takada T, Karasawa K, Watanabe T, Yorozu A, Tachibana H, Suzuki G, Hayabuchi N, Toba T, Yamada S: Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy. Int J Radiat Oncol Biol Phys; 2006 Jul 15;65(4):1045-50
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-institutional analysis of early squamous cell carcinoma of the hypopharynx treated with radical radiotherapy.
  • PURPOSE: To analyze the outcomes of patients with early hypopharyngeal cancer treated with radical radiotherapy (RT).
  • METHODS AND MATERIALS: Ten institutions combined the data from 115 patients with Stage I-II hypopharyngeal squamous cell carcinoma treated with definitive RT between 1990 and 2001.
  • Conventional fractionation was used in 98 patients and twice-daily RT in 17 patients; chemotherapy was combined with RT in 57 patients.
  • Of the 115 patients, 19 died of hypopharyngeal cancer, 10 died of second primary cancers, and 14 died of other causes during the study and follow-up periods.
  • CONCLUSIONS: Patients with early hypopharyngeal cancer tended to have a good prognosis after RT.
  • However, second malignancies had an adverse effect on the overall outcomes of patients with early hypopharyngeal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Hypopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / pathology. Radiotherapy Dosage. Recurrence. Retrospective Studies. Salvage Therapy. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16682142.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Aldoss IT, Plumb T, Zhen WK, Lydiatt DD, Ganti AK: Cetuximab in hemodialysis: a case report. Head Neck; 2009 Dec;31(12):1647-50
Hazardous Substances Data Bank. CETUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Concurrent chemoradiotherapy with cisplatin is the standard therapy for patients with unresectable locally advanced head and neck squamous cell carcinoma.
  • Concurrent chemoradiation with cetuximab has been approved in definitive treatment of locally advanced head and neck cancer.
  • METHODS AND RESULTS: We present the case of a 65-year-old man undergoing hemodialysis, with stage IVA squamous cell carcinoma of the hypopharynx.
  • He tolerated treatment well with minor side effects.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Renal Dialysis
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Cetuximab. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Humans. Kidney Failure, Chronic / diagnosis. Kidney Failure, Chronic / therapy. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19283845.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; PQX0D8J21J / Cetuximab
  •  go-up   go-down


23. Ghaffar S, Akhtar S, Ikram M, Imam SZ, Sepah YJ: Comparison of different treatment modalities in advanced laryngeal hypopharyngeal squamous cell carcinoma. J Coll Physicians Surg Pak; 2010 Mar;20(3):171-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of different treatment modalities in advanced laryngeal hypopharyngeal squamous cell carcinoma.
  • OBJECTIVE: To compare outcome of patients with advanced laryngeal hypopharyngeal squamous cell carcinoma treated surgically or with chemotherapy and/or radiotherapy.
  • METHODOLOGY: Medical records of already treated stage-III and IV squamous cell carcinoma of larynx/hypopharynx patients were reviewed.
  • Group-A comprised of patients treated with surgery +/- adjuvant therapy whereas non-surgically managed patients were labeled as group-B.
  • Kaplan Meier technique was used to estimate mean recurrence time with standard errors.
  • In group-A, 40% patients received postoperative adjuvant therapy while in group-B, 45% received concomitant chemoradiation.
  • Mean recurrence time was 1369+193 days.
  • In group-A, mean recurrence time was 2097+277 days.
  • The hazard ratio of recurrence in hypopharyngeal tumours was 1.5 times (95% CI 0.68, 3.30) as compared to tumours of larynx.
  • The hazard ratio of recurrence was 1.98 times (95% CI 0.99, 3.95) when both larynx and hypopharynx were involved as compared to when tumour was localized to larynx only.
  • No residual disease was noted at the completion of treatment in surgical group-A while 62% patients of the group-B had residual disease at the completion of treatment.
  • CONCLUSION: Statistically significant difference was noted in disease free outcome when stage-III and IV larynx hypopharynx cancer was managed surgically as compared to non-surgical management.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Hypopharyngeal Neoplasms / therapy. Laryngeal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20392379.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


24. Rodriguez CP, Adelstein DJ, Rybicki LA, Saxton JP, Lorenz RR, Wood BG, Strome M, Esclamado RM, Lavertu P, Carroll MA: Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy. Head Neck; 2008 Dec;30(12):1535-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Cisplatin and fluorouracil were given during weeks 1 and 4 of radiation to 115 patients with locoregionally advanced larynx or hypopharynx squamous cell cancer without cartilage invasion or laryngeal destruction.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Neoplasms, Squamous Cell / drug therapy. Neoplasms, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Kaplan-Meier Estimate. Laryngectomy. Male. Middle Aged. Patient Participation. Patient Selection. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc.
  • (PMID = 18704968.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Allegretto M, Selkaly H, Mackey JR: Intraoperative saline and gemcitabine irrigation improves tumour control in human squamous cell carcinoma-contaminated surgical wounds. J Otolaryngol; 2001 Apr;30(2):121-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative saline and gemcitabine irrigation improves tumour control in human squamous cell carcinoma-contaminated surgical wounds.
  • INTRODUCTION AND OBJECTIVES: The cure rates for advanced head and neck cancer patients have not changed substantially in the past few decades.
  • We developed a murine model of wound implantation with microscopic disease to assess the efficiency of tumour development and used this model to evaluate the effects on tumour development of surgical bed irrigation with three different solutions.
  • METHODS: Nonobese diabetic/severe combined immunodeficient mice were transplanted with the University of Michigan squamous cell carcinoma-22B cells derived from a human squamous cell carcinoma of the hypopharynx.
  • Two 1-cm surgical wounds were created on the backs of 20 mice and then instilled with a known quantity of tumour cells.
  • Ten of the mice had their wounds irrigated with 5 cc of water and then closed, 10 had their wounds irrigated with 5 cc of saline and then closed, and 10 had their wounds irrigated with 5 cc of 1-mM gemcitabine, a nonirritating chemotherapy drug with activity in human head and neck cancers.
  • After exposure to 2.5 x 10(6) cells, seven of eight surgical beds developed palpable tumours.
  • At postoperative day 17, 70% of the controls had evident tumour growth, whereas only 15% of the water irrigation group (p < .0005), 0% of the saline irrigation group (p < .0001), and 0% (p < .0001) of the gemcitabine irrigation group had developed tumours.
  • On day 56, 80% of the control mice and 75% of the water-irrigated mice group had developed palpable tumours.
  • CONCLUSIONS: In a xenograft model of tumour-cell wound contamination, irrigation with saline, water, or gemcitabine delayed tumour development.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacology. Carcinoma, Squamous Cell / pathology. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacology. Head and Neck Neoplasms / pathology. Neoplasm Seeding
  • [MeSH-minor] Animals. Humans. Intraoperative Care. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation. Sodium Chloride. Therapeutic Irrigation. Transplantation, Heterologous. Water

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11770954.001).
  • [ISSN] 0381-6605
  • [Journal-full-title] The Journal of otolaryngology
  • [ISO-abbreviation] J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 059QF0KO0R / Water; 0W860991D6 / Deoxycytidine; 451W47IQ8X / Sodium Chloride; B76N6SBZ8R / gemcitabine
  •  go-up   go-down






Advertisement